首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders
【24h】

Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders

机译:甲基酚酸盐注意力缺陷/多动障碍和合并物质使用障碍

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Patients with Attention Deficit/Hyperactivity Disorder (ADHD) and comorbid Substance Use Disorders (SUD) are increasingly being treated with central stimulant medication despite limited evidence for its effectiveness. Lack of longitudinal follow-up studies of dosing and adverse effects has resulted in conflicting treatment guidelines. This study aims to explore whether individuals with ADHD and comorbid SUD are treated with higher stimulant doses than individuals with ADHD only, and whether doses increase over time as a sign of tolerance, a core symptom of addiction. Information on methylphenidate doses for 14 314 Swedish adults, including 4870 individuals with comorbid SUD was obtained through linkages of Swedish national registers between 2006 and 2009. Differences in doses between patients with and without SUD were estimated using logistic regression while a linear regression model calculated time trends in mean doses. Individuals with SUD were prescribed higher methylphenidate doses than those without (OR day365 ; 2.12, 95% CI 1.81–2.47: OR day730 2.65, 95% CI 2.13–3.30). Patients with SUD were, two years after initiating stimulant treatment, prescribed approximately 40% higher doses compared to individuals with ADHD only. The results may suggest a need for increased doses in this population to achieve optimal ADHD symptom control. A tendency towards increasing doses during the first years of treatment, more pronounced in individuals with comorbid SUD, may reflect a reluctance to prescribe adequate doses due to lack of clinical guidelines. Mean doses stabilized after about two years in both groups, which does not lend support to continuously increasing tolerance over time. Highlights ? Patients with SUD use 40% higher methylphenidate doses than those with ADHD only ? Patients with SUD show high long-term adherence to methylphenidate treatment ? Patients with SUD are treated with methylphenidate without signs of tolerance
机译:摘要患者注意力缺陷/多动障碍(ADHD)和可嗜脱落物质使用障碍(SUD)越来越多地用中央兴奋剂药物治疗,尽管其有效性有限。对给药的缺乏纵向后续研究和不良反应导致治疗准则相互矛盾。本研究旨在探讨与仅具有ADHD的个体的刺激剂剂量是否具有较高的兴奋剂剂量的个体,以及剂量是否随着耐受性的迹象,成瘾的核心症状。通过2006年至2009年期间的瑞典国家寄存器的联系获得了有关14114瑞典瑞典成年剂的甲基酚剂量的信息,包括瑞典国家寄存器的联系。使用Logistic回归估计患者与没有SUD患者之间的剂量差异,而线性回归模型计算时间平均剂量的趋势。苏打水分的个体被规定比没有(或第365天; 2.12,95%CI 1.81-2.47:或Day730 2.65,95%Ci 2.13-3.30)规定的甲基酚酯剂量。苏打抑菌患者在启动兴奋剂治疗后两年,与仅具有ADHD的个体的单位规定了约40%的剂量。结果可能表明该人群中增加剂量增加,以实现最佳的ADHD症状控制。在治疗的第一年内增加剂量的趋势,在伴有合并泡沫的个人中更明显,可能反映出由于缺乏临床准则而产生足够的剂量。两组约两年后的平均剂量稳定,这不应借给持续增加耐受性随着时间的推移。强调 ?抑菌患者使用40%的甲基酚酯剂,而不是含有ADHD的剂量?毒品患者表现出高度长期粘附的甲基酚酯治疗? Sud患者用甲基酚酸盐治疗,没有耐受迹象

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号